BioStock: Leading transplant surgeon about Idogen’s cell therapy

The preclinical development work is progressing for Idogen’s cell therapy IDO T, which is intended to prevent organ rejection in transplantations, primarily kidney transplantations with a living donor. BioStock contacted Bo-Göran Ericzon, professor of Transplant Surgery at Karolinska Institutet, to clarify the value of innovative treatments in the field of transplantation.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/leading-transplant-surgeon-about-idogens-cell-therapy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se